PDCD1LG2 and skin squamous cell carcinoma: The FDA has recently approved the use of anti-PD-1 cemiplimab for advanced unresectable or metastatic cSCC based on its ability to block interactions between PD-1 and its ligands PD-L1 and PD-L2.25